These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2307025)

  • 1. Triple combination of retinoic acid, low concentration of cytarabine and dimethylformamide induces differentiation of human acute myeloid leukaemic blasts.
    Hassan HT; Rees JK
    Chemotherapy; 1990; 36(1):51-7. PubMed ID: 2307025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple combination of retinoic acid+aclacinomycin A+ dimethylformamide induces differentiation of human acute myeloid leukaemic blasts in primary culture.
    Hassan HT; Rees JK
    Anticancer Res; 1989; 9(3):647-51. PubMed ID: 2764511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple combination of retinoic acid plus actinomycin D plus dimethylformamide induces differentiation of human acute myeloid leukaemic blasts in primary culture.
    Hassan HT; Rees J
    Cancer Chemother Pharmacol; 1990; 26(1):26-30. PubMed ID: 2322987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple combination of retinoic acid + low concentration of cytosine arabinoside + hexamethylene bisacetamide induces differentiation of human AML blasts in primary culture.
    Hassan HT; Rees JK
    Hematol Oncol; 1989; 7(6):429-40. PubMed ID: 2807181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple combination of retinoic acid + 6-thioguanine + hexamethylene bisacetamide induces differentiation of human AML blasts in primary culture.
    Tawhid H; Rees J
    Leuk Res; 1990; 14(2):109-17. PubMed ID: 2314112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinoic acid alone and in combination with cytosine arabinoside induces differentiation of human myelomonocytic and monoblastic leukaemic cells.
    Hassan HT; Rees JK
    Hematol Oncol; 1988; 6(1):39-45. PubMed ID: 3422632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New synergistic combinations of differentiation inducing agents in the treatment of acute myeloid leukaemia.
    Hassan HT; Zyada LE; Ragab MH; Rees JK
    Eur J Clin Pharmacol; 1991; 41(6):531-6. PubMed ID: 1815964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A role for paclitaxel in the combination chemotherapy of acute myeloblastic leukaemia: preclinical cell culture studies.
    Curtis JE; Minkin S; Minden MD; McCulloch EA
    Br J Haematol; 1996 Nov; 95(2):354-63. PubMed ID: 8904892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation induction in myelodysplasia and acute myeloid leukaemia: use of synergistic drug combinations.
    Francis GE; Mufti GJ; Knowles SM; Berney JJ; Guimaraes JE; Secker-Walker LM; Hamblin TJ
    Leuk Res; 1987; 11(11):971-7. PubMed ID: 3480401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [All-trans retinoic acid combined with low-dose cytosine arabinoside treatment for acute myelogenous leukemia with trilineage myelodysplasia--a case report].
    Maeda N; Satake S; Okada Y; Asahara S; Hasuike N; Tamura M; Takata M; Tasaka K; Okutani T; Maeda Y; Tomofuji Y; Chinzei T; Saigo K
    Gan To Kagaku Ryoho; 2001 Mar; 28(3):407-10. PubMed ID: 11265415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia.
    Crews KR; Gandhi V; Srivastava DK; Razzouk BI; Tong X; Behm FG; Plunkett W; Raimondi SC; Pui CH; Rubnitz JE; Stewart CF; Ribeiro RC
    J Clin Oncol; 2002 Oct; 20(20):4217-24. PubMed ID: 12377965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
    Gandhi V; Estey E; Keating MJ; Plunkett W
    J Clin Oncol; 1993 Jan; 11(1):116-24. PubMed ID: 8418222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytosine arabinoside (ara-C) and cis-dichlorodiammineplatinum II (cisplatin) alone and in combination: effects on acute myeloblastic leukemia blast cells in culture and in vivo.
    Wang YF; Curtis JE; Lipton J; Minkin S; McCulloch EA
    Leukemia; 1991 Jun; 5(6):522-7. PubMed ID: 1711641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decitabine combined with all-trans retinoic acid as treatment in a case of primary myelofibrosis transforming into acute myeloid leukaemia.
    Lin Y; Lin R; Zhou G; Liu Y; Dong W; Cao Y; Xie X; Gu W
    J Int Med Res; 2019 Feb; 47(2):1064-1071. PubMed ID: 30616420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
    Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
    Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [High dosage ARA-C in combination with mitoxantrone in therapy of acute myeloid leukemia in childhood. Initial results of the AML BFM-85 recurrence study].
    Ritter J; Creutzig U; Henze G; Jürgens H; Bode U; Prindull G; Schellong G
    Onkologie; 1987 Feb; 10(1):24-7. PubMed ID: 3295622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
    Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
    Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.